Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients Journal Article
| Authors: | Inaoka, R. J.; Jungbluth, A. A.; Gnjatic, S.; Ritter, E.; Hanson, N. C.; Frosina, D.; Tassello, J.; Etto, L. Y.; Bortoluzzo, A. B.; Alves, A. C.; Colleoni, G. W. B. |
| Article Title: | Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients |
| Abstract: | Background Based on their tumor-associated expression pattern, cancer/testis antigens (CTAs) are considered potential targets for cancer immunotherapy. We aim to evaluate the expression of CTAs in non-Hodgkin's lymphoma (NHL) samples and the ability of these patients to elicit spontaneous humoral immune response against CTAs. Methods Expression of MAGE-A family, CT7/MAGEC1, CT10/MAGE-C2, GAGE and NY-ESO-1 was analyzed by immunohistochemistry in a tissue microarray generated from 106 NHL archival cases. The humoral response against 19 CTAs was tested in 97 untreated NHL serum samples using ELISA technique. Results 11.3 % of NHL tumor samples expressed at least 1 CTA. MAGE-A family (6.6 %), GAGE (5.7 %) and NY-ESO-1(4.7 %) were the most frequently expressed antigens. We found no statistically significant correlation between CTA positivity and clinical parameters such as NHL histological subtype, Ann Arbor stage, international prognostic index score, response to treatment and overall survival. Humoral response against at least 1 CTA was observed in 16.5 % of NHL serum samples. However, overall seroreactivity was low, and strong titers ([1:1000) were observed in only two diffuse large B-cell lymphomas patients against CT45. Conclusion Our findings are in agreement with most of published studies in this field to date and suggest an overall low expression of CTAs in NHL patients. However, as many new CTAs have been described recently and some of them are found to be highly expressed in NHL cell lines and tumor samples, further studies exploring the expression of different panels of CTAs are needed to evaluate their role as candidates for immunotherapy in NHL patients. © Springer-Verlag 2012. |
| Keywords: | immunohistochemistry; adolescent; adult; controlled study; human tissue; treatment response; aged; unclassified drug; major clinical study; overall survival; review; cancer patient; cancer staging; antigen expression; cancer immunotherapy; retrospective study; enzyme linked immunosorbent assay; nonhodgkin lymphoma; blood sampling; non-hodgkin's lymphoma; cancer testis antigen; ny eso 1 antigen; antigen detection; melanoma antigen; melanoma antigen c1; large cell lymphoma; brazil; cancer tissue; tissue microarray; cancer classification; protein family; humoral immunity; cancer/testis antigens; antibody titer; gage antigen; melanoma antigen c2; humoral response; cancer prognosis; international prognostic scoring system |
| Journal Title: | Cancer Immunology, Immunotherapy |
| Volume: | 61 |
| Issue: | 12 |
| ISSN: | 0340-7004 |
| Publisher: | Springer |
| Date Published: | 2012-12-01 |
| Start Page: | 2207 |
| End Page: | 2214 |
| Language: | English |
| DOI: | 10.1007/s00262-012-1285-6 |
| PROVIDER: | scopus |
| PUBMED: | 22638551 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 January 2013" - "CODEN: CIIMD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work